N4 Pharma PLC Covid-19 Proof of Concept Update (8226Y)
14 September 2020 - 8:00AM
UK Regulatory
TIDMN4P
RNS Number : 8226Y
N4 Pharma PLC
14 September 2020
14 September 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Covid-19 Proof of Concept Update and move to in vivo study
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing, a novel delivery system for cancer treatments and
vaccines, provides an update on its Covid-19 proof of concept work
utilising Nuvec(R) loaded with Coronavirus plasmid.
As announced on 12 August 2020, stage 2 of the proof of concept
work was successfully completed with the transfection of HEK (Human
Embryonic Kidney) cells of Nuvec(R) loaded with Coronavirus plasmid
in vitro. Following the completion of stage 3 of the proof of
concept work and a review of the results, the Company is continuing
to explore the utility of Nuvec(R) with the Coronavirus plasmid and
will progress to an in vivo study in due course.
Whilst the single intradermal injection used in the stage 3 pre
(pilot) in vivo study did not result in a measurable expression of
the spike protein in the target cells of the murine target, neither
did the positive control. Additional exploratory studies will
continue to understand the translation potency of the Coronavirus
plasmid including optimisation of Nuvec(R) plasmid loading. With
this in mind and taken together with previous positive data, the
Company has decided to proceed to a full in vivo study to
demonstrate the capability of Nuvec(R) to generate Covid-19
specific antibodies.
The Company is in the process of scoping the programme of
studies required.
Nigel Theobald, Chief Executive Officer, commented: "The initial
pilot work of stage 3 of the Covid-19 proof of concept work was
narrow in its scope and, having reviewed the results, we have taken
the decision to move to a full in vivo study to establish an immune
response through the production of antibodies. In undertaking the
work we aim to demonstrate Nuvec(R)'s capabilities both as a
potential delivery technology for multiple vaccines as well as for
Covid-19 specifically. I look forward to providing further updates
in due course."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
IFC Advisory Ltd Tel: +44(0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDKXLFFBKLXBBB
(END) Dow Jones Newswires
September 14, 2020 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jul 2023 bis Jul 2024